Methods and compositions for the sustained release of chromium
View Patent ↗Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.
1. A composition comprising:
a chromium complex comprising:
an amount of a fast-acting chromium complex; and
an amount of a slow-acting chromium complex; wherein the fast-acting chromium complex is absorbed more quickly by an individual to whom it is administered than the slow-acting chromium complex;
wherein the amount of a fast acting chromium complex and the amount of the slow-reacting chromium complex are formulated to have a molar ratio of chromium between 1:10 and 10:1.
2. The composition of claim 1 , wherein the chromium complex is a hydrophobic chromium complex.
3. The composition of claim 1 , wherein the fast-acting chromium complex is hydrophilic and the slow-acting chromium complex is lipophilic.
4. The composition of claim 1 , wherein the slow-acting chromium complex is lipophilic.
5. The composition of claim 1 , wherein the fast-acting chromium complex is hydrophilic.
6. The composition of claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:8 and 8:1.
7. The composition of claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:4 and 4:1.
8. The composition of claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:2 and 2:1.
9. The composition of claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium of about 1:1.
10. The composition of claim 1 , wherein the fast-acting chromium complex is a chromium histidinate complex.
11. The composition of claim 1 , wherein the fast-acting chromium complex is a chromium nicotinate complex.
12. The composition of claim 1 , wherein the fast-acting chromium complex is selected from the group consisting of chromium acetate, chromium chloride, chromium histidinate, and chromium nicotinate, or any combination thereof.
13. The composition of claim 1 , wherein the fast-acting chromium complex is selected from the group consisting of chromium histidinate, chromium trihistidinate, chromium polyhistidinate, or any combination thereof.
14. The composition of claim 1 , further comprising metformin.
15. The composition of claim 1 , further comprising a pharmaceutically acceptable vehicle.
16. The composition of claim 1 , wherein the slow-acting chromium complex is selected from the group consisting of chromium picolinate, chromium tripicolinate, or a combination thereof.
17. The composition of claim 1 , wherein the slow-acting chromium complex is chromium picolinate.
18. The composition of claim 1 , wherein the slow-acting chromium complex is chromium tripicolinate.
19. The composition of claim 1 , wherein the slow-acting chromium complex provides a glucose lowering effect.
20. The composition of claim 1 , wherein the slow-acting chromium complex provides a glucose stabilization effect for at least 10 hours.